Literature DB >> 2982144

Formation of a transformed follicle is necessary but not sufficient for development of an avian leukosis virus-induced lymphoma.

T W Baba, E H Humphries.   

Abstract

Avian leukosis virus (ALV) infection of susceptible chickens induces bursal lymphomas after a latent period of several months. The clonal development of these B-cell tumors is believed to be a multistep process. Histopathological changes, referred to as transformed follicles, occur within the target organ soon after virus infection and may represent a proximal stage of lymphomagenesis. To establish further the significance of this lesion and its relationship to the subsequent development of lymphomas, we have compared the incidence of transformed follicles observed in animals susceptible or resistant to ALV-induced tumor development. During the 8 weeks following ALV infection, transformed follicles were detected in 82% of the susceptible animals and in 11% of the resistant animals. These results indicate that the incidence of transformed follicles in these animals correlates with their susceptibility to lymphoma development. Furthermore, each transformed follicle does not develop into a tumor. These observations suggest that the formation of a transformed follicle is necessary but not sufficient for lymphoma development.

Entities:  

Mesh:

Year:  1985        PMID: 2982144      PMCID: PMC397002          DOI: 10.1073/pnas.82.1.213

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  9 in total

1.  Patterns of viral interference in the avian leukosis and sarcoma complex.

Authors:  P K Vogt; R Ishizaki
Journal:  Virology       Date:  1966-11       Impact factor: 3.616

2.  Multiple arrangements of viral DNA and an activated host oncogene in bursal lymphomas.

Authors:  G S Payne; J M Bishop; H E Varmus
Journal:  Nature       Date:  1982-01-21       Impact factor: 49.962

3.  Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis.

Authors:  W S Hayward; B G Neel; S M Astrin
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

4.  Two distinct candidate transforming genes of lymphoid leukosis virus-induced neoplasms.

Authors:  G M Cooper; P E Neiman
Journal:  Nature       Date:  1981-08-27       Impact factor: 49.962

5.  Clonal analysis of the integration and expression of endogenous avian retroviral DNA acquired by exogenous viral infection.

Authors:  E H Humphries; R Allen; C Glover
Journal:  J Virol       Date:  1981-08       Impact factor: 5.103

6.  Molecular cloning and nucleotide sequence of a transforming gene detected by transfection of chicken B-cell lymphoma DNA.

Authors:  G Goubin; D S Goldman; J Luce; P E Neiman; G M Cooper
Journal:  Nature       Date:  1983-03-10       Impact factor: 49.962

7.  Differential response to avian leukosis virus infection exhibited by two chicken lines.

Authors:  T W Baba; E H Humphries
Journal:  Virology       Date:  1984-05       Impact factor: 3.616

8.  Avian leukosis virus infection: analysis of viremia and DNA integration in susceptible and resistant chicken lines.

Authors:  T W Baba; E H Humphries
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

9.  Transforming genes of neoplasms induced by avian lymphoid leukosis viruses.

Authors:  G M Cooper; P E Neiman
Journal:  Nature       Date:  1980-10-16       Impact factor: 49.962

  9 in total
  22 in total

1.  Analysis of gene expression during myc oncogene-induced lymphomagenesis in the bursa of Fabricius.

Authors:  P E Neiman; A Ruddell; C Jasoni; G Loring; S J Thomas; K A Brandvold; J Burnside; J Delrow
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

2.  Persistence of Marek's disease virus in a subpopulation of B cells that is transformed by avian leukosis virus, but not in normal bursal B cells.

Authors:  E Fynan; T M Block; J DuHadaway; W Olson; D L Ewert
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

3.  An avian retrovirus expressing chicken pp59c-myc possesses weak transforming activity distinct from v-myc that may be modulated by adjacent normal cell neighbors.

Authors:  E J Filardo; E H Humphries
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

4.  bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its noncoding RNA.

Authors:  W Tam; D Ben-Yehuda; W S Hayward
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

5.  Downregulation of chicken interleukin-17 receptor A during Eimeria infection.

Authors:  Woo H Kim; Jipseol Jeong; Ae R Park; Dongjean Yim; Suk Kim; Hong H Chang; Seung-Hak Yang; Dong-Hee Kim; Hyun S Lillehoj; Wongi Min
Journal:  Infect Immun       Date:  2014-06-30       Impact factor: 3.441

6.  5' long terminal repeats of myc-associated proviruses appear structurally intact but are functionally impaired in tumors induced by avian leukosis viruses.

Authors:  M M Goodenow; W S Hayward
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

7.  Ongoing diversification of the rearranged immunoglobulin light-chain gene in a bursal lymphoma cell line.

Authors:  S Kim; E H Humphries; L Tjoelker; L Carlson; C B Thompson
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

8.  Tissue-specific lability and expression of avian leukosis virus long terminal repeat enhancer-binding proteins.

Authors:  A Ruddell; M L Linial; M Groudine
Journal:  Mol Cell Biol       Date:  1989-12       Impact factor: 4.272

9.  Avian proto-myc genes promoted by defective or nondefective retroviruses are single-hit transforming genes in primary cells.

Authors:  R P Zhou; P H Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

10.  Differential selection of cells with proviral c-myc and c-erbB integrations after avian leukosis virus infection.

Authors:  M Gong; H L Semus; K J Bird; B J Stramer; A Ruddell
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.